LLY

918.04

-1.5%↓

JNJ

237.29

-1.12%↓

ABBV

209.67

-5.52%↓

NVS

150.84

-2.63%↓

AZN

189.69

-1.13%↓

LLY

918.04

-1.5%↓

JNJ

237.29

-1.12%↓

ABBV

209.67

-5.52%↓

NVS

150.84

-2.63%↓

AZN

189.69

-1.13%↓

LLY

918.04

-1.5%↓

JNJ

237.29

-1.12%↓

ABBV

209.67

-5.52%↓

NVS

150.84

-2.63%↓

AZN

189.69

-1.13%↓

LLY

918.04

-1.5%↓

JNJ

237.29

-1.12%↓

ABBV

209.67

-5.52%↓

NVS

150.84

-2.63%↓

AZN

189.69

-1.13%↓

LLY

918.04

-1.5%↓

JNJ

237.29

-1.12%↓

ABBV

209.67

-5.52%↓

NVS

150.84

-2.63%↓

AZN

189.69

-1.13%↓

Search

Simulations Plus Inc

Atvērts

SektorsVeselības aprūpe

11.71 -3.46

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

11.61

Max

12.16

Galvenie mērījumi

By Trading Economics

Ienākumi

1.4M

676K

Pārdošana

961K

18M

Dividenžu ienesīgums

0.48

Peļņas marža

3.67

Darbinieki

212

EBITDA

-3M

2.3M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+59.4% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

0.48%

2.40%

Nākamie ieņēmumi

2026. g. 2. apr.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-124M

244M

Iepriekšējā atvēršanas cena

15.17

Iepriekšējā slēgšanas cena

11.71

Ziņu noskaņojums

By Acuity

50%

50%

156 / 351 Rangs Healthcare

Simulations Plus Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 17. marts 22:42 UTC

Peļņas

Prudential PLC 2025 Adjusted Operating Profit Rises

2026. g. 17. marts 21:40 UTC

Peļņas

Alimentation Couche-Tard Records Higher Profit, Revenue in 3Q

2026. g. 17. marts 23:56 UTC

Tirgus saruna

BHP's Next CEO Likely to Build On Existing Strategic Direction -- Market Talk

2026. g. 17. marts 23:46 UTC

Tirgus saruna

Nikkei May Rise After Recent Selloffs -- Market Talk

2026. g. 17. marts 23:42 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 17. marts 23:42 UTC

Tirgus saruna

RBA's Return to Policy Tightening Will Work -- Market Talk

2026. g. 17. marts 23:38 UTC

Tirgus saruna

Gold Edges Lower on Possible Position Adjustments Before FOMC Decision -- Market Talk

2026. g. 17. marts 23:24 UTC

Tirgus saruna

Global Energy Roundup: Market Talk

2026. g. 17. marts 23:24 UTC

Tirgus saruna

New Woodside CEO Seen as Low-Risk Appointment -- Market Talk

2026. g. 17. marts 22:22 UTC

Tirgus saruna

BHP Hands Reins to Growth-Focused Executive -- Market Talk

2026. g. 17. marts 22:20 UTC

Peļņas

Prudential PLC 2025 New Business Profit $2.78B Vs. $2.46B >2378.HK

2026. g. 17. marts 22:20 UTC

Peļņas

Prudential PLC 2025 Adj Operating Profit $3.31B Vs. $3.13B >2378.HK

2026. g. 17. marts 22:07 UTC

Peļņas

Nvidia Says It Is Restarting Production of AI Chips for Sale in China -- WSJ

2026. g. 17. marts 22:05 UTC

Peļņas

ZTO Express (Cayman): Frank Zhen Wei to Resign From Board

2026. g. 17. marts 22:04 UTC

Peļņas

ZTO Express (Cayman): Board Approves Repurchase of Up to $1.5B of Shares Over Next 24 Months >ZTO

2026. g. 17. marts 22:03 UTC

Peļņas

ZTO Express (Cayman) Raises Semiannual Dividend to 39c Vs. 30c >ZTO

2026. g. 17. marts 22:01 UTC

Peļņas

ZTO Express (Cayman) 4Q Adj EPS 47c >ZTO

2026. g. 17. marts 22:01 UTC

Peļņas

ZTO Express (Cayman) 4Q Rev $2.08B >ZTO

2026. g. 17. marts 22:01 UTC

Peļņas

ZTO Express (Cayman) 4Q EPS 47c >ZTO

2026. g. 17. marts 21:26 UTC

Peļņas

Oklo Stock Wavers After Earnings, but the Nuclear Start-Up Has Good News -- Barrons.com

2026. g. 17. marts 21:09 UTC

Peļņas

Couche-Tard: 12 Company-Operated Stores Acquired During 3Q

2026. g. 17. marts 21:08 UTC

Peļņas

Couche-Tard 3Q Consolidated Same-Store Merchandise Revenue Up 2% >ATD.T

2026. g. 17. marts 21:08 UTC

Peļņas

Couche-Tard 3Q Adj EPS 81c >ATD.T

2026. g. 17. marts 21:07 UTC

Peļņas

Couche-Tard 3Q EPS 82c >ATD.T

2026. g. 17. marts 21:06 UTC

Peļņas

Couche-Tard 3Q Rev $21.8B >ATD.T

2026. g. 17. marts 21:05 UTC

Peļņas

Couche-Tard 3Q Adj EPS 81c >ATD.T

2026. g. 17. marts 21:05 UTC

Peļņas

Couche-Tard 3Q Rev $21.8B >ATD.T

2026. g. 17. marts 21:05 UTC

Peļņas

Couche-Tard 3Q EPS 82c >ATD.T

2026. g. 17. marts 21:05 UTC

Peļņas

Couche-Tard 3Q Net $757.2M >ATD.T

2026. g. 17. marts 20:50 UTC

Tirgus saruna
Galvenie ziņu notikumi

Energy & Utilities Roundup: Market Talk

Salīdzinājums

Cenas izmaiņa

Simulations Plus Inc Prognoze

Cenas mērķis

By TipRanks

59.4% augšup

Prognoze 12 mēnešiem

Vidējais 19 USD  59.4%

Augstākais 19 USD

Zemākais 19 USD

Pamatojoties uz 4 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Simulations Plus Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

4 ratings

2

Pirkt

2

Turēt

0

Pārdot

Noskaņojums

By Acuity

156 / 351 Rangs Veselības aprūpe

Ziņu noskaņojums

Neutral

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat